Abstract
Tinnitus, a phantom sensation experienced by people around the world, currently is endured without a known cure. Some find the condition tolerable, while others are tortured on a daily basis from the incessant phantom noises. For those who seek treatment, oftentimes, they have a comorbid condition (e.g., depression, anxiety, insomnia), which is treated pharmaceutically. These products aim to reduce the comorbities associated with tinnitus thereby minimizing the overall burden present. Because of the phantom nature of tinnitus, it is often compared to neurologic pain. Since pain can be managed with pharmaceutical options, it is reasonable to assume that similar agents might work to alleviate tinnitus. The effects of antidepressants, benzodiazepines, anticonvulsants, and glutamate antagonists are reviewed in this paper. Table 1 summarizes the pharmaceutical products discussed. Due to the variety of comorbid factors and potential causes of tinnitus, there may not be one pharmaceutical treatment that will combat every type of tinnitus. Nevertheless, a product that finally addresses the true cause of tinnitus, and not just its comorbidities, will benefit millions of people worldwide.
Keywords: Angiotensin-converting enzyme (ACE), anticonvulsants, antidepressants, benzodiazepines, COX2, cyclooxygenase (COX)1, glutamate antagonists, tinnitus, vitamins.
Current Neuropharmacology
Title:The Management and Outcomes of Pharmacological Treatments for Tinnitus
Volume: 13 Issue: 5
Author(s): Devon Beebe Palumbo, Kathleen Joos, Dirk De Ridder and Sven Vanneste
Affiliation:
Keywords: Angiotensin-converting enzyme (ACE), anticonvulsants, antidepressants, benzodiazepines, COX2, cyclooxygenase (COX)1, glutamate antagonists, tinnitus, vitamins.
Abstract: Tinnitus, a phantom sensation experienced by people around the world, currently is endured without a known cure. Some find the condition tolerable, while others are tortured on a daily basis from the incessant phantom noises. For those who seek treatment, oftentimes, they have a comorbid condition (e.g., depression, anxiety, insomnia), which is treated pharmaceutically. These products aim to reduce the comorbities associated with tinnitus thereby minimizing the overall burden present. Because of the phantom nature of tinnitus, it is often compared to neurologic pain. Since pain can be managed with pharmaceutical options, it is reasonable to assume that similar agents might work to alleviate tinnitus. The effects of antidepressants, benzodiazepines, anticonvulsants, and glutamate antagonists are reviewed in this paper. Table 1 summarizes the pharmaceutical products discussed. Due to the variety of comorbid factors and potential causes of tinnitus, there may not be one pharmaceutical treatment that will combat every type of tinnitus. Nevertheless, a product that finally addresses the true cause of tinnitus, and not just its comorbidities, will benefit millions of people worldwide.
Export Options
About this article
Cite this article as:
Beebe Palumbo Devon, Joos Kathleen, De Ridder Dirk and Vanneste Sven, The Management and Outcomes of Pharmacological Treatments for Tinnitus, Current Neuropharmacology 2015; 13 (5) . https://dx.doi.org/10.2174/1570159X13666150415002743
DOI https://dx.doi.org/10.2174/1570159X13666150415002743 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Calcium-Independent Membrane Damage by Venom Phospholipases A2
Protein & Peptide Letters Buprenorphine-Mediated Transition from Opioid Agonist to Antagonist Treatment: State of the Art and New Perspectives
Current Drug Abuse Reviews Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Readjusting the Glucocorticoid Balance: An Opportunity for Modulators of 11β -Hydroxysteroid Dehydrogenase Type 1 Activity?
Endocrine, Metabolic & Immune Disorders - Drug Targets Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Controlled and Continuous Release Ocular Drug Delivery Systems: Pros and Cons
Current Drug Delivery Functional Food with Some Health Benefits, So Called Superfood: A Review
Current Nutrition & Food Science The Nitric Oxide Prodrug JS-K and Its Structural Analogues as Cancer Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Treatment of Pulmonary Thromboembolism in Patients with Systemic Blood Pressure Stability and Right Ventricular Dysfunction
Current Respiratory Medicine Reviews Environmental Toxicants as Extrinsic Epigenetic Factors for Parkinsonism: Studies Employing Transgenic C. elegans Model
CNS & Neurological Disorders - Drug Targets Mastering the Treatment of Diabetes Mellitus Type 1 in Childhood and Adolescence
Current Pediatric Reviews An Algorithm to Classify Amino Acid Sequences into Protein Groups of Bothrops jararacussu Venomous Gland
Protein & Peptide Letters Editorial: Limited Utility of the Handgrip Test for the Diagnosis of Diabetic Cardiovascular Autonomic Neuropathy: “There’s Time Enough, But None to Spare”
Current Vascular Pharmacology Cerebral Vasoreactivity in a Fabry Disease Patient
Current Medical Imaging Current Landscape on Development of Phenylalanine and Toxicity of its Metabolites - A Review
Current Drug Safety Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Polymorphic Drug Metabolism in Anaesthesia
Current Drug Metabolism Potential Effect of Angiotensin II Receptor Blockade in Adipose Tissue and Bone
Current Pharmaceutical Design Antibody Therapy of Acute and Chronic Leukemias
Current Pharmaceutical Biotechnology